NCT04631653

Verisee Software for Diabetic Retinopathy Screening

The Clinical Benefit of an Artificial Intelligence Software Implementation on Diabetic Retinopathy Screening

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,000 (estimated)
• Sponsor: Taichung Veterans General Hospital · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The investigators aim to improve the diagnostic accuracy and the clinical referral rate for diabetic retinopathy by using a deep learning-based software.

Detailed description

Diabetic retinopathy (DR) is the leading cause of blindness among working-age patients with type 2 diabetes. According to previous studies, early screening and timely treatment can reduce the risk of worsening DR and blindness. International guidelines recommend that screening for DR be performed at least once every year for patients with type 2 diabetes. The investigators will implement a validated deep learning-based software, VeriSee®, in clinics, and evaluate the benefits on diagnostic accuracy and the clinical referral rate for diabetic retinopathy after implementation of this software.

Conditions

• Diabetic Retinopathy

Interventions

Type	Name	Description
DEVICE	VeriSee®	Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®

Timeline

• Start date: 2020-12-01
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2020-11-17
• Last updated: 2020-11-17

Locations

1 site across 1 country: Taiwan